Lmo4 Deficiency Enhances Susceptibility to Cisplatin-Induced Cochlear Apoptosis and Hearing Loss

Area of Science:

• Ototoxicity research
• Molecular mechanisms of hearing loss
• Cancer therapeutics side effects

Background:

• Cisplatin is a vital chemotherapy drug but causes ototoxicity, limiting its use.
• Oxidative and nitrative stress from cisplatin contribute to cochlear cell death and reduced LIM domain only 4 (LMO4) expression.
• LMO4 is a transcriptional regulator implicated in cellular processes.

Purpose of the Study:

• To investigate the direct role of cochlear LMO4 in cisplatin-induced ototoxicity.
• To elucidate the molecular pathways involving LMO4 in protecting against hearing loss.

Main Methods:

• Utilized a Lmo4 conditional knockout mouse model (Lmo4^lox/lox; Gfi1^Cre/+) with hair cell-specific LMO4 deletion.
• Assessed hearing function using auditory brainstem response (ABR) thresholds and otoacoustic emissions (OAEs).
• Examined the expression of phosphorylated STAT3 and activated caspase 3 via immunostaining post-cisplatin treatment.

Main Results:

• Hair cell-specific LMO4 deletion did not affect baseline hearing or cochlear structure.
• Cisplatin treatment significantly increased ABR thresholds in Lmo4 knockout mice compared to controls.
• LMO4 deficiency impaired STAT3 activation and enhanced caspase 3 activation in cochlear hair cells after cisplatin exposure.

Conclusions:

• Cochlear LMO4 plays a significant otoprotective role against cisplatin-induced ototoxicity.
• The LMO4/STAT3 pathway is crucial for the cellular defense mechanism against cisplatin-induced hearing loss.
• Reduced LMO4 expression following cisplatin treatment compromises this protective pathway, leading to ototoxicity.